• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)
临床输血与检验

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (2): 211-214.DOI: 10.3969/j.issn.1671-2587.2020.02.024

• 临床检验 • 上一篇    下一篇

硼替佐米联合化疗对多发性骨髓瘤的治疗效果及对VEGF、IL-6、IL-17的影响

聂丽容, 李庆华, 梁亮, 何红华, 马境志   

  1. 524000 湛江,广东医科大学附属医院血液内科
  • 收稿日期:2018-07-27 出版日期:2020-04-20 发布日期:2020-04-16
  • 通讯作者: 李庆华,女,广东韶关人,副主任医师,硕士,主要从事血液病学临床工作,（E-mail）urdfq44@163.com。
  • 作者简介:聂丽容（1981-）,女,广东惠州人,主治医师,硕士,主要从事血液病学临床工作,（Tel）13763051087（E-mail）qweof99@163.com。

The Effect of Bortezomib-Combined Chemotherapy on Multiple Myeloma and VEGF, IL-6 and IL-17

NIE Li-rong, LI Qing-hua, LIANG Liang, et al   

  1. Department of Hematology, the Hospital of Guangdong Medical University, Zhanjiang 524000
  • Received:2018-07-27 Online:2020-04-20 Published:2020-04-16

PDF

883

摘要： 目的 探究硼替佐米联合化疗对多发性骨髓瘤的治疗效果,以及对患者血管内皮生长因子（vascular endothelial growth factor,VEGF）、白细胞介素6（interleukin 6,IL-6）、IL-17的影响。方法 选取本院于2016年5月~2018年5月收治的80例多发性骨髓瘤患者,分为传统化疗组（53例）和硼替佐米组（27例）。传统化疗组给予患者常规疗法,硼替佐米组给予沙利度胺、硼替佐米、阿霉素、地塞米松。采用ELISA双抗体夹心法检测VEGF、IL-6、IL-17;琼脂糖凝胶电泳检测M蛋白;溴甲酚绿法检测球蛋白;骨髓穿刺细胞形态学检查骨髓浆细胞数;免疫透射比浊法检测血红蛋白。比较治疗效果和不良反应率。结果 治疗后硼替佐米组患者VEGF、IL-6、IL-17表达水平低于传统化疗组患者（P<0.05）;治疗后硼替佐米组患者M蛋白、骨髓浆细胞数及球蛋白低于传统化疗组,血红蛋白高于传统化疗组（P<0.05）;硼替佐米组患者的治疗总有效率明显高于传统化疗组;硼替佐米组患者的总不良反应率低于传统化疗组（P<0.05）;VEGF、IL-6、IL-17的表达水平与病情严重程度成正相关。结论 硼替佐米联合化疗对多发性骨髓瘤的治疗效果显著,安全性高。

关键词: 多发性骨髓瘤, M蛋白, 浆细胞, 促炎因子

Abstract: Objective To study the efficacy of bortezomib-combined chemotherapy in treatment of multiple myeloma and its effect on the levels of VEGF, IL-6 and IL-17. Methods Eighty inpatients were divided into routine group and bortezomib group. The drugs in the bortezomib group included thalidomide, bortezomib, doxorubicin and dexamethasone. VEGF, IL-6 and IL-17 were detected by ELISA and M protein was tested by agarose gel electrophoresis. Determination of globulin was performed by bromocresol green method, the number of bone marrow plasma cells （BMPCs） was examined by bone marrow puncture, and hemoglobin was detected by immunoturbidimetric assay. Results The levels of VEGF, IL-6 and IL-17 in the bortezomib group were significantly decreased compared with those in the routine chemotherapy group （P<0.05） after treatments. The levels of M protein, BMPCs and globulin were notably lower but the hemoglobin was higher in the bortezomib group than in the routine group （P<0.05）. The total therapeutic efficacy of bortezomib group was distinctively elevated. Additionally, bortezomib-combined therapy remarkably reduced the frequency of adverse reactions （P<0.05）. The levels of VEGF, IL-6 and IL-17 were found to be positively related to the severity of the disease. Conclusion Bortezomib-combined chemotherapy is effective and safe in treatment of multiple myeloma.

Key words: Multiple myeloma, M Protein, Plasma cells, Proinflammatory factors

中图分类号: